Market Outlook
The global Duchenne Muscular Dystrophy (DMD) Therapeutics market size was valued at USD 1367.7 million in 2022 and is forecast to a readjusted size of USD 14630 million by 2029 with a CAGR of 40.3% during review period.
Duchenne muscular dystrophy, sometimes shortened to DMD or just Duchenne, is a rare genetic disease. It predominantly affects males, but, in rare cases, can also affect females. Duchenne causes the muscles in the body to become weak and damaged over time and is eventually fatal. The genetic change that causes Duchenne—a mutation in the DMD gene—happens before birth and can be inherited, or new mutations in the gene can occur spontaneously. Muscle weakness becomes increasingly noticeable between the ages of 3 and 5, and most patients use a wheelchair by the time they are 12. During adolescence, heart and breathing muscles weaken, leading to serious, life-threatening complications.
By region, North America has the highest market share, reaching 70.66% in 2019. Sarepta Therapeutics and PTC Therapeutics hold almost the whole market.
This report is a detailed and comprehensive analysis for global Duchenne Muscular Dystrophy (DMD) Therapeutics market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global Duchenne Muscular Dystrophy (DMD) Therapeutics market size and forecasts, in consumption value ($ Million), 2018-2029
Global Duchenne Muscular Dystrophy (DMD) Therapeutics market size and forecasts by region and country, in consumption value ($ Million), 2018-2029
Global Duchenne Muscular Dystrophy (DMD) Therapeutics market size and forecasts, by Type and by Application, in consumption value ($ Million), 2018-2029
Global Duchenne Muscular Dystrophy (DMD) Therapeutics market shares of main players, in revenue ($ Million), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Duchenne Muscular Dystrophy (DMD) Therapeutics
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Duchenne Muscular Dystrophy (DMD) Therapeutics market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Key Market Players
Sarepta Therapeutics
PTC Therapeutics
Pfizer
Bristol-Myers Squibb
Italfarmaco
Santhera Pharmaceuticals
Segmentation By Type
Exondys
Emflaza
Translarna
Segmentation By Application
Hospitals
Clinics
Home Care
Segmentation By Region
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
South America (Brazil, Argentina and Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
Market SWOT Analysis
What are the strengths of the Duchenne Muscular Dystrophy (DMD) therapeutics market in 2025?
The market for DMD therapeutics in 2025 benefits from significant advances in gene therapy, innovative treatments like exon skipping, and increased collaboration between pharmaceutical companies and research institutes. These breakthroughs can improve patient outcomes and create a strong pipeline of novel drugs.
What are the weaknesses in the DMD therapeutics market?
High treatment costs, limited access to healthcare in low-income regions, and challenges in the delivery of gene-based therapies are significant weaknesses. Moreover, the complexity of managing DMD with current therapies may limit their widespread effectiveness.
What opportunities exist in the DMD therapeutics market by 2025?
There are significant opportunities to expand clinical trials, particularly in underrepresented populations and regions. Moreover, the growth of personalized medicine and gene editing techniques offers promising new avenues to enhance therapeutic options and potentially provide a cure for DMD.
What threats are present in the DMD therapeutics market in 2025?
Regulatory hurdles, safety concerns regarding long-term use of new therapies, and the risk of competition from alternative treatments or technologies can threaten market growth. Additionally, patent expirations and market entry of generics could reduce profit margins for pioneering treatments.
Market PESTEL Analysis
What are the political factors impacting the Duchenne Muscular Dystrophy (DMD) therapeutics market in 2025?
Political factors such as government funding for rare disease research and policy support for orphan drugs will play a major role. Legislative support for more accessible healthcare systems and pricing regulations will also influence the affordability and accessibility of DMD therapies.
How do economic factors affect the DMD therapeutics market?
Economic factors, such as healthcare spending, insurance coverage, and the global economic downturn, could affect the affordability of DMD treatments. High drug costs may limit access, especially in low- and middle-income countries, while wealthy nations may see a rise in healthcare expenditure dedicated to rare diseases.
What social factors impact the DMD therapeutics market?
Increasing awareness about Duchenne Muscular Dystrophy (DMD) through social initiatives and advocacy groups will drive demand for better treatments. The rising number of patients and families seeking better care options, coupled with a growing focus on rare disease management, will shape the market’s trajectory.
How do technological factors influence the DMD therapeutics market?
Technological advancements in gene therapy, exon skipping, and personalized medicine are revolutionizing the DMD therapeutics landscape. Innovations in drug delivery systems and diagnostic tools will accelerate the development of more effective treatments, improving patient outcomes.
What environmental factors affect the DMD therapeutics market?
Environmental factors such as sustainability practices in pharmaceutical production and the global push for eco-friendly policies could impact the production costs and availability of DMD therapies. The environmental impact of biotech research also plays a role in shaping public and corporate responsibility in the industry.
What legal factors influence the DMD therapeutics market?
Legal factors, including intellectual property laws, patent protection for new therapies, and regulatory approvals from bodies like the FDA, will significantly shape the development and commercialization of DMD treatments. Additionally, legal battles over pricing and access to rare disease treatments may affect market dynamics.
Market SIPOC Analysis
What are the suppliers in the Duchenne Muscular Dystrophy (DMD) therapeutics market in 2025?
Suppliers include pharmaceutical companies, biotech firms, research institutions, and raw material providers for drug manufacturing. These suppliers provide the necessary compounds, gene-editing technologies, and clinical trial support for developing DMD therapies.
Who are the inputs into the DMD therapeutics market?
Inputs include research data, genetic materials, clinical trial results, regulatory approvals, and funding. These inputs also involve collaboration between academic researchers, healthcare professionals, and regulatory agencies to bring new treatments to market.
What processes are involved in the DMD therapeutics market?
The processes include research and development (R&D) of new therapies, preclinical and clinical testing, regulatory approval processes, marketing, and distribution of the drugs. Additionally, continuous monitoring for patient safety and post-market surveillance are integral to the therapeutic lifecycle.
What are the outputs of the DMD therapeutics market?
The outputs are the approved DMD therapies that improve patients' quality of life and slow the disease progression. These include gene therapies, exon-skipping treatments, and other novel drugs that reach the market following successful trials and approvals.
Who are the customers in the DMD therapeutics market?
Customers are patients diagnosed with Duchenne Muscular Dystrophy, their families, healthcare providers, and specialized clinics. Insurance companies and public health systems are also key customers, as they help facilitate access to therapies.
Market Porter's Five Forces
What is the threat of new entrants in the DMD therapeutics market in 2025?
The threat of new entrants is moderate. While the high cost of research and development and regulatory hurdles make entry difficult, advancements in gene therapies and increasing funding for rare diseases may attract new players. However, the market’s complexity and established players with patent protection provide some barriers to new entrants.
What is the bargaining power of suppliers in the DMD therapeutics market?
The bargaining power of suppliers is moderate to high. Pharmaceutical companies rely on specialized suppliers for raw materials, gene-editing technologies, and other critical inputs. Limited availability of key technologies and materials, such as those used in gene therapy, gives suppliers significant leverage over pricing and availability.
What is the bargaining power of buyers in the DMD therapeutics market?
The bargaining power of buyers is relatively low. Patients and families often have few alternatives due to the rarity of DMD and the lack of effective treatments. However, healthcare systems and insurance providers can exert some influence over pricing and access to therapies, especially in regions with strong healthcare policies.
What is the threat of substitute products in the DMD therapeutics market?
The threat of substitutes is low. Due to the specialized nature of DMD treatments, there are few alternatives that can directly replace the existing therapies. However, the market must continue to innovate to stay ahead of emerging technologies like gene editing, which may offer alternative approaches to traditional drug treatments.
What is the intensity of competitive rivalry in the DMD therapeutics market?
The competitive rivalry is moderate. While there are a few major players dominating the market with therapies in late-stage development, the race to develop more effective and personalized treatments is fierce. The market is likely to see increased competition as new therapies and technologies emerge, leading to ongoing innovation and differentiation.
Market Upstream Analysis
What are the key raw materials involved in the DMD therapeutics market?
The key raw materials include genetic materials, chemical compounds, and biologics required for the synthesis of gene therapies, protein replacement therapies, and other drug formulations. Additionally, reagents and vectors used in gene delivery are critical to the development of advanced treatments for DMD.
What are the main sources of research and development for DMD therapeutics?
R&D for DMD therapeutics primarily comes from academic institutions, biotechnology firms, and pharmaceutical companies. Collaborations with hospitals and clinical research organizations (CROs) are crucial for conducting trials and understanding the disease mechanisms. These entities also work closely with regulatory bodies to meet safety and efficacy standards.
What are the major technological drivers in the upstream process of DMD therapeutics?
Technological advancements in gene editing, particularly CRISPR-Cas9, exon skipping techniques, and gene delivery vectors, are major drivers. These technologies enable more precise treatments, improving the efficiency of developing therapies that target the genetic mutations responsible for DMD. Additionally, innovations in diagnostic tools facilitate early-stage identification of patients for targeted interventions.
What are the challenges faced in the upstream process of DMD therapeutics?
Challenges in the upstream process include the high cost and complexity of developing gene-based therapies, limited availability of clinical trial participants due to the rarity of the disease, and the difficulty of producing large quantities of biologic drugs. Regulatory hurdles related to the safety and long-term efficacy of novel treatments also pose significant obstacles.
What role do suppliers play in the upstream process of the DMD therapeutics market?
Suppliers play a crucial role by providing raw materials, specialized equipment, and advanced technologies for the production of DMD therapeutics. They supply critical resources like viral vectors for gene therapy, plasmids for gene editing, and specialized reagents for research and development, helping to accelerate the creation of viable treatments.
Market Midstream Analysis
What are the key activities in the midstream process of the DMD therapeutics market?
The key activities include clinical trials, regulatory approval processes, and the manufacturing scale-up of therapeutics. During this stage, companies focus on ensuring the safety and efficacy of therapies through rigorous testing, while preparing for large-scale production and distribution upon regulatory approval.
What challenges are faced in the midstream process of DMD therapeutics?
Challenges include lengthy clinical trial timelines, difficulty in recruiting suitable patient populations due to the rarity of DMD, and managing the complexities of regulatory requirements across different regions. Additionally, ensuring the scalability and consistency of production for gene therapies is a major hurdle.
What role do clinical trials play in the midstream process of DMD therapeutics?
Clinical trials are critical in the midstream process as they determine the safety, dosage, and efficacy of DMD therapies. Successful trials not only validate the therapeutic potential but also support the drug's journey through the regulatory approval process, which is essential for market access.
How does the regulatory environment impact the midstream process of DMD therapeutics?
The regulatory environment plays a significant role in determining the speed and feasibility of bringing a therapy to market. Regulations around safety, efficacy, and clinical trial design must be strictly adhered to, and the approval process can be lengthy, impacting market entry timelines and the overall cost of therapy development.
What is the role of partnerships in the midstream process of DMD therapeutics?
Partnerships between pharmaceutical companies, research institutions, and healthcare providers are crucial for advancing therapies through clinical trials and regulatory processes. Collaborative efforts help pool resources, expertise, and patient access, accelerating the development of effective treatments while navigating the complex regulatory landscape.
Market Downstream Analysis
What are the key activities in the downstream process of the DMD therapeutics market?
The key activities in the downstream process include marketing and distribution of approved therapies, patient education, and post-market surveillance. This phase also involves ongoing monitoring of treatment outcomes, gathering real-world data, and ensuring patients have access to the therapies through various healthcare systems and insurance networks.
What challenges are faced in the downstream process of DMD therapeutics?
Challenges include high treatment costs, patient access issues, particularly in low-income regions, and the need for long-term monitoring of therapy safety and effectiveness. Additionally, limited healthcare infrastructure in certain regions may hinder the distribution and availability of life-changing treatments for DMD.
How does patient access to DMD therapies impact the downstream process?
Patient access is a significant factor, as many DMD treatments are expensive and may not be covered under all insurance plans. This can delay or limit access, particularly in developing countries or for patients without adequate healthcare coverage. Ensuring widespread access is key to the overall success of these therapies in the market.
What is the role of post-market surveillance in the downstream process?
Post-market surveillance is crucial in assessing the long-term safety and effectiveness of DMD therapies. It provides essential data on how treatments perform outside of clinical trials, helping identify any adverse effects and ensuring that ongoing regulatory compliance is maintained.
How does the competitive landscape affect the downstream process of DMD therapeutics?
The competitive landscape can influence the downstream process by encouraging companies to focus on differentiating their therapies in terms of pricing, patient access, and ongoing patient support. As new therapies enter the market, there may be a need to develop strategic partnerships with healthcare providers or adjust marketing strategies to maintain market share.
Chapter 1, to describe Duchenne Muscular Dystrophy (DMD) Therapeutics product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Duchenne Muscular Dystrophy (DMD) Therapeutics, with revenue, gross margin and global market share of Duchenne Muscular Dystrophy (DMD) Therapeutics from 2018 to 2023.
Chapter 3, the Duchenne Muscular Dystrophy (DMD) Therapeutics competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and Duchenne Muscular Dystrophy (DMD) Therapeutics market forecast, by regions, type and application, with consumption value, from 2024 to 2029.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War
Chapter 12, the key raw materials and key suppliers, and industry chain of Duchenne Muscular Dystrophy (DMD) Therapeutics.
Chapter 13, to describe Duchenne Muscular Dystrophy (DMD) Therapeutics research findings and conclusion.
1 Market Overview
1.1 Product Overview and Scope of Duchenne Muscular Dystrophy (DMD) Therapeutics
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Duchenne Muscular Dystrophy (DMD) Therapeutics by Type
1.3.1 Overview: Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type: 2018 Versus 2022 Versus 2029
1.3.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value Market Share by Type in 2022
1.3.3 Exondys
1.3.4 Emflaza
1.3.5 Translarna
1.4 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market by Application
1.4.1 Overview: Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application: 2018 Versus 2022 Versus 2029
1.4.2 Hospitals
1.4.3 Clinics
1.4.4 Home Care
1.5 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size & Forecast
1.6 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Forecast by Region
1.6.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Region: 2018 VS 2022 VS 2029
1.6.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Region, (2018-2029)
1.6.3 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Prospect (2018-2029)
1.6.4 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Prospect (2018-2029)
1.6.5 Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Prospect (2018-2029)
1.6.6 South America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Prospect (2018-2029)
1.6.7 Middle East and Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Prospect (2018-2029)
2 Company Profiles
2.1 Sarepta Therapeutics
2.1.1 Sarepta Therapeutics Details
2.1.2 Sarepta Therapeutics Major Business
2.1.3 Sarepta Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Product and Solutions
2.1.4 Sarepta Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Sarepta Therapeutics Recent Developments and Future Plans
2.2 PTC Therapeutics
2.2.1 PTC Therapeutics Details
2.2.2 PTC Therapeutics Major Business
2.2.3 PTC Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Product and Solutions
2.2.4 PTC Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 PTC Therapeutics Recent Developments and Future Plans
2.3 Pfizer
2.3.1 Pfizer Details
2.3.2 Pfizer Major Business
2.3.3 Pfizer Duchenne Muscular Dystrophy (DMD) Therapeutics Product and Solutions
2.3.4 Pfizer Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Pfizer Recent Developments and Future Plans
2.4 Bristol-Myers Squibb
2.4.1 Bristol-Myers Squibb Details
2.4.2 Bristol-Myers Squibb Major Business
2.4.3 Bristol-Myers Squibb Duchenne Muscular Dystrophy (DMD) Therapeutics Product and Solutions
2.4.4 Bristol-Myers Squibb Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Bristol-Myers Squibb Recent Developments and Future Plans
2.5 Italfarmaco
2.5.1 Italfarmaco Details
2.5.2 Italfarmaco Major Business
2.5.3 Italfarmaco Duchenne Muscular Dystrophy (DMD) Therapeutics Product and Solutions
2.5.4 Italfarmaco Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Italfarmaco Recent Developments and Future Plans
2.6 Santhera Pharmaceuticals
2.6.1 Santhera Pharmaceuticals Details
2.6.2 Santhera Pharmaceuticals Major Business
2.6.3 Santhera Pharmaceuticals Duchenne Muscular Dystrophy (DMD) Therapeutics Product and Solutions
2.6.4 Santhera Pharmaceuticals Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Santhera Pharmaceuticals Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Share by Players (2018-2023)
3.2 Market Share Analysis (2022)
3.2.1 Market Share of Duchenne Muscular Dystrophy (DMD) Therapeutics by Company Revenue
3.2.2 Top 3 Duchenne Muscular Dystrophy (DMD) Therapeutics Players Market Share in 2022
3.2.3 Top 6 Duchenne Muscular Dystrophy (DMD) Therapeutics Players Market Share in 2022
3.3 Duchenne Muscular Dystrophy (DMD) Therapeutics Market: Overall Company Footprint Analysis
3.3.1 Duchenne Muscular Dystrophy (DMD) Therapeutics Market: Region Footprint
3.3.2 Duchenne Muscular Dystrophy (DMD) Therapeutics Market: Company Product Type Footprint
3.3.3 Duchenne Muscular Dystrophy (DMD) Therapeutics Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 Market Size Segment by Type
4.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value and Market Share by Type (2018-2023)
4.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Forecast by Type (2024-2029)
5 Market Size Segment by Application
5.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value Market Share by Application (2018-2023)
5.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Forecast by Application (2024-2029)
6 North America
6.1 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value by Type (2018-2029)
6.2 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value by Application (2018-2029)
6.3 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country
6.3.1 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value by Country (2018-2029)
6.3.2 United States Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Forecast (2018-2029)
6.3.3 Canada Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Forecast (2018-2029)
6.3.4 Mexico Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Forecast (2018-2029)
7 Europe
7.1 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value by Type (2018-2029)
7.2 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value by Application (2018-2029)
7.3 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country
7.3.1 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value by Country (2018-2029)
7.3.2 Germany Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Forecast (2018-2029)
7.3.3 France Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Forecast (2018-2029)
7.3.4 United Kingdom Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Forecast (2018-2029)
7.3.5 Russia Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Forecast (2018-2029)
7.3.6 Italy Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Forecast (2018-2029)
8 Asia-Pacific
8.1 Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value by Type (2018-2029)
8.2 Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value by Application (2018-2029)
8.3 Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Region
8.3.1 Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value by Region (2018-2029)
8.3.2 China Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Forecast (2018-2029)
8.3.3 Japan Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Forecast (2018-2029)
8.3.4 South Korea Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Forecast (2018-2029)
8.3.5 India Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Forecast (2018-2029)
8.3.6 Southeast Asia Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Forecast (2018-2029)
8.3.7 Australia Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Forecast (2018-2029)
9 South America
9.1 South America Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value by Type (2018-2029)
9.2 South America Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value by Application (2018-2029)
9.3 South America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country
9.3.1 South America Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value by Country (2018-2029)
9.3.2 Brazil Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Forecast (2018-2029)
9.3.3 Argentina Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Forecast (2018-2029)
10 Middle East & Africa
10.1 Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value by Type (2018-2029)
10.2 Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value by Application (2018-2029)
10.3 Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country
10.3.1 Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value by Country (2018-2029)
10.3.2 Turkey Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Forecast (2018-2029)
10.3.3 Saudi Arabia Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Forecast (2018-2029)
10.3.4 UAE Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Forecast (2018-2029)
11 Market Dynamics
11.1 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Drivers
11.2 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Restraints
11.3 Duchenne Muscular Dystrophy (DMD) Therapeutics Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
11.5 Influence of COVID-19 and Russia-Ukraine War
11.5.1 Influence of COVID-19
11.5.2 Influence of Russia-Ukraine War
12 Industry Chain Analysis
12.1 Duchenne Muscular Dystrophy (DMD) Therapeutics Industry Chain
12.2 Duchenne Muscular Dystrophy (DMD) Therapeutics Upstream Analysis
12.3 Duchenne Muscular Dystrophy (DMD) Therapeutics Midstream Analysis
12.4 Duchenne Muscular Dystrophy (DMD) Therapeutics Downstream Analysis
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
List of Tables
Table 1. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value by Region (2018-2023) & (USD Million)
Table 4. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value by Region (2024-2029) & (USD Million)
Table 5. Sarepta Therapeutics Company Information, Head Office, and Major Competitors
Table 6. Sarepta Therapeutics Major Business
Table 7. Sarepta Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Product and Solutions
Table 8. Sarepta Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 9. Sarepta Therapeutics Recent Developments and Future Plans
Table 10. PTC Therapeutics Company Information, Head Office, and Major Competitors
Table 11. PTC Therapeutics Major Business
Table 12. PTC Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Product and Solutions
Table 13. PTC Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 14. PTC Therapeutics Recent Developments and Future Plans
Table 15. Pfizer Company Information, Head Office, and Major Competitors
Table 16. Pfizer Major Business
Table 17. Pfizer Duchenne Muscular Dystrophy (DMD) Therapeutics Product and Solutions
Table 18. Pfizer Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 19. Pfizer Recent Developments and Future Plans
Table 20. Bristol-Myers Squibb Company Information, Head Office, and Major Competitors
Table 21. Bristol-Myers Squibb Major Business
Table 22. Bristol-Myers Squibb Duchenne Muscular Dystrophy (DMD) Therapeutics Product and Solutions
Table 23. Bristol-Myers Squibb Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 24. Bristol-Myers Squibb Recent Developments and Future Plans
Table 25. Italfarmaco Company Information, Head Office, and Major Competitors
Table 26. Italfarmaco Major Business
Table 27. Italfarmaco Duchenne Muscular Dystrophy (DMD) Therapeutics Product and Solutions
Table 28. Italfarmaco Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 29. Italfarmaco Recent Developments and Future Plans
Table 30. Santhera Pharmaceuticals Company Information, Head Office, and Major Competitors
Table 31. Santhera Pharmaceuticals Major Business
Table 32. Santhera Pharmaceuticals Duchenne Muscular Dystrophy (DMD) Therapeutics Product and Solutions
Table 33. Santhera Pharmaceuticals Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 34. Santhera Pharmaceuticals Recent Developments and Future Plans
Table 35. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue (USD Million) by Players (2018-2023)
Table 36. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Share by Players (2018-2023)
Table 37. Breakdown of Duchenne Muscular Dystrophy (DMD) Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3)
Table 38. Market Position of Players in Duchenne Muscular Dystrophy (DMD) Therapeutics, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2022
Table 39. Head Office of Key Duchenne Muscular Dystrophy (DMD) Therapeutics Players
Table 40. Duchenne Muscular Dystrophy (DMD) Therapeutics Market: Company Product Type Footprint
Table 41. Duchenne Muscular Dystrophy (DMD) Therapeutics Market: Company Product Application Footprint
Table 42. Duchenne Muscular Dystrophy (DMD) Therapeutics New Market Entrants and Barriers to Market Entry
Table 43. Duchenne Muscular Dystrophy (DMD) Therapeutics Mergers, Acquisition, Agreements, and Collaborations
Table 44. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value (USD Million) by Type (2018-2023)
Table 45. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value Share by Type (2018-2023)
Table 46. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value Forecast by Type (2024-2029)
Table 47. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value by Application (2018-2023)
Table 48. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value Forecast by Application (2024-2029)
Table 49. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value by Type (2018-2023) & (USD Million)
Table 50. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value by Type (2024-2029) & (USD Million)
Table 51. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value by Application (2018-2023) & (USD Million)
Table 52. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value by Application (2024-2029) & (USD Million)
Table 53. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value by Country (2018-2023) & (USD Million)
Table 54. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value by Country (2024-2029) & (USD Million)
Table 55. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value by Type (2018-2023) & (USD Million)
Table 56. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value by Type (2024-2029) & (USD Million)
Table 57. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value by Application (2018-2023) & (USD Million)
Table 58. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value by Application (2024-2029) & (USD Million)
Table 59. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value by Country (2018-2023) & (USD Million)
Table 60. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value by Country (2024-2029) & (USD Million)
Table 61. Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value by Type (2018-2023) & (USD Million)
Table 62. Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value by Type (2024-2029) & (USD Million)
Table 63. Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value by Application (2018-2023) & (USD Million)
Table 64. Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value by Application (2024-2029) & (USD Million)
Table 65. Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value by Region (2018-2023) & (USD Million)
Table 66. Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value by Region (2024-2029) & (USD Million)
Table 67. South America Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value by Type (2018-2023) & (USD Million)
Table 68. South America Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value by Type (2024-2029) & (USD Million)
Table 69. South America Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value by Application (2018-2023) & (USD Million)
Table 70. South America Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value by Application (2024-2029) & (USD Million)
Table 71. South America Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value by Country (2018-2023) & (USD Million)
Table 72. South America Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value by Country (2024-2029) & (USD Million)
Table 73. Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value by Type (2018-2023) & (USD Million)
Table 74. Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value by Type (2024-2029) & (USD Million)
Table 75. Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value by Application (2018-2023) & (USD Million)
Table 76. Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value by Application (2024-2029) & (USD Million)
Table 77. Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value by Country (2018-2023) & (USD Million)
Table 78. Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value by Country (2024-2029) & (USD Million)
Table 79. Duchenne Muscular Dystrophy (DMD) Therapeutics Raw Material
Table 80. Key Suppliers of Duchenne Muscular Dystrophy (DMD) Therapeutics Raw Materials
List of Figures
Figure 1. Duchenne Muscular Dystrophy (DMD) Therapeutics Picture
Figure 2. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value Market Share by Type in 2022
Figure 4. Exondys
Figure 5. Emflaza
Figure 6. Translarna
Figure 7. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 8. Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value Market Share by Application in 2022
Figure 9. Hospitals Picture
Figure 10. Clinics Picture
Figure 11. Home Care Picture
Figure 12. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 13. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 14. Global Market Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value (USD Million) Comparison by Region (2018 & 2022 & 2029)
Figure 15. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value Market Share by Region (2018-2029)
Figure 16. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value Market Share by Region in 2022
Figure 17. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 18. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 19. Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 20. South America Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 21. Middle East and Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 22. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Share by Players in 2022
Figure 23. Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2022
Figure 24. Global Top 3 Players Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share in 2022
Figure 25. Global Top 6 Players Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share in 2022
Figure 26. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value Share by Type (2018-2023)
Figure 27. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share Forecast by Type (2024-2029)
Figure 28. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value Share by Application (2018-2023)
Figure 29. Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Share Forecast by Application (2024-2029)
Figure 30. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value Market Share by Type (2018-2029)
Figure 31. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value Market Share by Application (2018-2029)
Figure 32. North America Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value Market Share by Country (2018-2029)
Figure 33. United States Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 34. Canada Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 35. Mexico Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 36. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value Market Share by Type (2018-2029)
Figure 37. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value Market Share by Application (2018-2029)
Figure 38. Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value Market Share by Country (2018-2029)
Figure 39. Germany Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 40. France Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 41. United Kingdom Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 42. Russia Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 43. Italy Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 44. Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value Market Share by Type (2018-2029)
Figure 45. Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value Market Share by Application (2018-2029)
Figure 46. Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value Market Share by Region (2018-2029)
Figure 47. China Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 48. Japan Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 49. South Korea Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 50. India Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 51. Southeast Asia Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 52. Australia Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 53. South America Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value Market Share by Type (2018-2029)
Figure 54. South America Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value Market Share by Application (2018-2029)
Figure 55. South America Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value Market Share by Country (2018-2029)
Figure 56. Brazil Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 57. Argentina Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 58. Middle East and Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value Market Share by Type (2018-2029)
Figure 59. Middle East and Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value Market Share by Application (2018-2029)
Figure 60. Middle East and Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value Market Share by Country (2018-2029)
Figure 61. Turkey Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 62. Saudi Arabia Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 63. UAE Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value (2018-2029) & (USD Million)
Figure 64. Duchenne Muscular Dystrophy (DMD) Therapeutics Market Drivers
Figure 65. Duchenne Muscular Dystrophy (DMD) Therapeutics Market Restraints
Figure 66. Duchenne Muscular Dystrophy (DMD) Therapeutics Market Trends
Figure 67. Porters Five Forces Analysis
Figure 68. Manufacturing Cost Structure Analysis of Duchenne Muscular Dystrophy (DMD) Therapeutics in 2022
Figure 69. Manufacturing Process Analysis of Duchenne Muscular Dystrophy (DMD) Therapeutics
Figure 70. Duchenne Muscular Dystrophy (DMD) Therapeutics Industrial Chain
Figure 71. Methodology
Figure 72. Research Process and Data Source
